Skip to main content
SpringerLink
Log in
Book cover

Métastases vertébrales pp 155–163Cite as

Métastases vertébrales des cancers du rein

  • Chapter

  • 369 Accesses

Abstrait

En France, le cancer du rein représente 2,1 à 2,6 % des cancers de l’adulte avec une fréquence plus élevée entre 50 et 70 ans et une prédominance masculine. Il est responsable de 2 % de la mortalité par cancer.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Althausen P, Althausen A, Candace Jennings L, Mankin HJ (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80: 1103–9

    Google Scholar 

  2. Blatcher E, Johnson DE, Haynie TP (1985) Value of routine radionucleide bone scans in renal cell carcinoma. Urology 26: 432–4

    Article  Google Scholar 

  3. Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH (2002) 131I-cG250 monoclonal antibody immunoscintigraphy versus (18F) FDG-PET imaging in patients with metastatic renal cell carcinoma. A comparative study. Nucl Med Commun 23: 229–36

    Article  PubMed  CAS  Google Scholar 

  4. Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinoma. Urology 33: 167–170

    Article  PubMed  CAS  Google Scholar 

  5. Cohen HT, Mc Govern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477–90

    Google Scholar 

  6. De Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP (1988) Prognostic factors of adult metastatic renal cell carcinoma: a multivariate analysis. Semin Surg Oncol 4: 149–54

    Article  PubMed  Google Scholar 

  7. Dekernion JB, Rammings KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120: 148–52

    PubMed  CAS  Google Scholar 

  8. Dilhuydy MS, Durieux A, de Clermont H, Pasticier G, Monteil, Ravaud A (2006) PET scan for decision-making in metastatic renal cell carcinoma: a single institution evaluation. Br J Cancer (soumis)

    Google Scholar 

  9. Dineen MK, Pastore RD, Emrich LJ, Huben RP (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 140: 277–9

    PubMed  CAS  Google Scholar 

  10. Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310–3

    PubMed  CAS  Google Scholar 

  11. Escudier B, Szczylik C, Eisen T et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY-43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23: 380s (abstr.4510)

    Google Scholar 

  12. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-?.Eur J Cancer 9: 1310–4

    Article  Google Scholar 

  13. Gold PJ, Fefer A, Thompson JA (1996) Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 14: 216–22

    PubMed  CAS  Google Scholar 

  14. Halperin EC, Harisiadis L (1983) The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51: 614–7

    Article  PubMed  CAS  Google Scholar 

  15. Henriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S (1992) Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scan J Urol Nephrol 26: 363–6

    CAS  Google Scholar 

  16. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261–6

    PubMed  CAS  Google Scholar 

  17. Lee J, Hodgson D, Chow E, Bezjak A, Catton P, Tsuji D, O’Brien M, Danjoux C, Hayter C, Warde P, Gospodarowicz MK (2005) A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104: 1894–900

    Article  PubMed  Google Scholar 

  18. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10: 6397S–6403S

    Article  PubMed  CAS  Google Scholar 

  19. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Meckhail TM, Olencki TE, Elson P, Bukowski RM (2003) F-18 fluorodeoxyglucose of distant metastases from renal cell carcinoma. J Clin Oncol 21: 3995–4000

    Article  PubMed  Google Scholar 

  20. Maldazys JD, Dekernion JB (1986) Prognostic factors in metastatic renal cell carcinoma. J Urol 136: 376–9

    PubMed  CAS  Google Scholar 

  21. Mehdizadeh S, Alaghband-Zadeh J, Gusterson B, Arlot M, Bradbeer JN, Loveridge N (1989) Bone resorption and circulating PTH-like bioactivityin an animal model of hypercalcemia of malignancy. Biochem Biophys Res Commun 161: 1166–71

    Article  PubMed  CAS  Google Scholar 

  22. Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97: 973–7

    PubMed  CAS  Google Scholar 

  23. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117: 272–5

    PubMed  CAS  Google Scholar 

  24. Motzer RJ, Rini BI, Michaelson MD et al. (2005) Phase 2 trials of SU 11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Proc Am Soc Clin Oncol 23: 380s (abstr.4508)

    Google Scholar 

  25. Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–8

    Article  PubMed  Google Scholar 

  26. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Tubiana N, Escudier B (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized Percy Quattro trial. Proc Am Soc Clin Oncol 23: 1093s (abstr.4511)

    Google Scholar 

  27. Nissenson RA, Strewler GJ, Williams RD, Leung SC (1985) Activation of the parathyroid hormone receptor-adenylate cyclase system in osteosarcoma cells by a human renal carcinoma factor. Cancer Res 45: 5358–63

    PubMed  CAS  Google Scholar 

  28. O’Dea MJ, Zinke H, Utz DC, Bernatz PE (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120: 540–2

    PubMed  CAS  Google Scholar 

  29. Onufrey V, Mohiuddin M (1985) Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 11: 2007–9

    PubMed  CAS  Google Scholar 

  30. Palmer PA, Vinke J, Philip T, Négrier S, Atzpodien J, Kirchner H et al. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475–480

    PubMed  CAS  Google Scholar 

  31. Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scoot AM (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166: 825–30

    Article  PubMed  CAS  Google Scholar 

  32. Ravaud A, Négrier S, Cany L, Merrouche Y, Le Guillou M, Blay JY et al. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69: 1111–4

    PubMed  CAS  Google Scholar 

  33. Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C et al. (1998) Subcutaneous interleukin-2; interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. J Clin Oncol 16: 2728–32

    PubMed  CAS  Google Scholar 

  34. Ravaud A, Debled M (1999) Present achievements in the medical treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 31: 77–87

    Article  PubMed  CAS  Google Scholar 

  35. Ravaud A, Dilhuydy MS, Huchet A, Pédeboscq S, Maire JP (2005) Current strategy in the treatment of metastatic renal cell carcinoma. Curr Cancer Ther Review 1: 127–38

    Article  CAS  Google Scholar 

  36. Rini B, Rixe O, Bukowski R et al. (2005) AG-013739, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23: 380s (abstr.4509)

    Google Scholar 

  37. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Eonhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 907–13

    Article  PubMed  CAS  Google Scholar 

  38. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J (2002) The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cancer. Clin Nephrol 57: 56–62

    PubMed  CAS  Google Scholar 

  39. Seto E, Segall GM, Terris MK (2000) Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 55: 286xvi–286 xvii

    Article  Google Scholar 

  40. Shimizu TS, Uchida T, Shibata Y, Satoh J, Sugihara S, Maehara Y (1994) A case of posttherapeutic sclerotic change of bone metastasis from renal cell carcinoma which proved histopathologically to be complete response. Urol Int 53: 172–5

    Article  PubMed  CAS  Google Scholar 

  41. Shiraishi S, Ohkubo Y, Saito T (1979) Regression of multiple osseous metastatic renal cell carcinoma. Clin Orthop 138: 246–9

    PubMed  Google Scholar 

  42. Skinner DG, Colvin RB, Vermillon CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma: clinical and pathological study of 309 cases. Cancer 28: 1165–71

    Article  PubMed  CAS  Google Scholar 

  43. Strewler GJ, Williams RD, Nissenson RA (1983) Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors. J Clin Invest 71: 769–74

    Article  PubMed  CAS  Google Scholar 

  44. Suva LJ, Winslow GA, Wettenhall REH et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893–6

    Article  PubMed  CAS  Google Scholar 

  45. Swanson DA, Orovan WL, Johnson DE, Giacco G (1981) Osseous metastases secondary to renal cell carcinoma. Urology 18: 556–61

    Article  PubMed  CAS  Google Scholar 

  46. Van der Poel HG, Roukema JA, Horenblas S, Van Geel AN, Debruyne FMJ (1997) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35: 197–203

    Article  Google Scholar 

  47. Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–34

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Hôpital Saint-André, 1, rue Jean Burguet, 33075, Bordeaux Cedex

    Alain Ravaud

  2. Hôpital Saint-André, 1, rue Jean Burguet, 33075, Bordeaux Cedex

    Marie-Sarah Dilhuydy (Service radiothérapie)

Authors
  1. Alain Ravaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Sarah Dilhuydy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Chirurgie Orthopédique et Réparatrice, Hôpital Pellegrin-Tripode, Place Amélie-Raba-Léon, 33076, Bordeaux Cedex

    Vincent Pointillart

  2. Service d’oncologie médicale, Hôpital Saint-André - CHU Bordeaux, 1, rue Jean Burguet, 33075, Bordeaux Cedex

    Alain Ravaud

  3. Institut Bergonié, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    Jean Palussière

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Ravaud, A., Dilhuydy, MS. (2007). Métastases vertébrales des cancers du rein. In: Pointillart, V., Ravaud, A., Palussière, J. (eds) Métastases vertébrales. Springer, Paris. https://doi.org/10.1007/978-2-287-33744-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-33744-4_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-33743-7

  • Online ISBN: 978-2-287-33744-4

Publish with us

Policies and ethics

Search

Navigation